Isomorphic Labs vs Schrödinger (2026)
Both predict how molecules bind their targets, and they are offered in very different ways. Isomorphic Labs, founded in 2021 as an Alphabet business building on AlphaFold, runs its Drug Design Engine for structure prediction, pocket finding, binding affinity and antibody modeling, and makes it available only through strategic collaborations with pharmaceutical companies. Schrödinger licenses physics based simulation software, such as Glide, FEP+ and LiveDesign, that a team installs and runs on its own programs, with machine learning used alongside the physics. Isomorphic reports large gains over AlphaFold 3 on public benchmarks but publishes no code, weights or method for its engine. Schrödinger's methods are documented and in wide use. The choice is between a partnership for access to a closed engine and software you can run and inspect.
- A unified engine for protein ligand structure, pocket identification, binding affinity and antibody antigen modeling, described in February 2026.
- Reported benchmark gains, including more than double AlphaFold 3's accuracy on the least similar protein ligand cases.
- The team behind AlphaFold 3, released with Google DeepMind in 2024.
- Software a team licenses and runs itself, with no partnership required.
- Documented physics based methods, including FEP+ for binding affinity, used widely across the industry.
- LiveDesign for collaborative design, with a module for training predictive models on a team's own data.
This comparison is published by AI Health Index, an independent research platform that compares healthcare AI vendors objectively. Isomorphic Labs and Schrödinger are each graded against the same capability taxonomy, from each vendor's own public materials and the regulatory record, under the AI Health Index verification standard. No vendor pays for placement, and no vendor has reviewed this page. How this evidence is graded
Plain facts
| Fact | Isomorphic Labs | Schrödinger |
|---|---|---|
| Primary category | Drug Discovery AI | Drug Discovery AI |
| Founded | 2021 | Not recorded |
| Headquarters | London, United Kingdom | New York, NY |
| Website | isomorphiclabs.com | schrodinger.com |
Side by Side
Select any grade to read the note behind it.
Each vendor in one paragraph
Written to be quoted whole. Each paragraph opens the AI Health Index profile of the vendor: what the product is, who buys it and what it does.
Isomorphic Labs is a London based AI drug design company founded in 2021 by Sir Demis Hassabis, who leads it as chief executive. It was launched from DeepMind as an Alphabet company, and with Google DeepMind it released AlphaFold 3 in May 2024. Its Isomorphic Labs Drug Design Engine (IsoDDE), introduced in February 2026, joins proprietary models for protein ligand structure prediction, binding site discovery, binding affinity and antibody antigen modeling with generative agents that design molecules.
Source: AI Health Index, September 2026
Computational chemistry software company (Nasdaq: SDGR) whose physics based molecular simulation platform is licensed to pharmaceutical, biotechnology, industrial and academic organizations, alongside a proprietary therapeutics pipeline built on the same platform.
Source: AI Health Index, September 2026
Questions buyers ask
How are Isomorphic Labs and Schrödinger priced and sold?
Drug companies work with Isomorphic Labs through negotiated research collaborations, opened through a dedicated partnering contact.
As a listed company Schrödinger reports software revenue, customer metrics and pipeline spend, which describes its own economics rather than what a licensee pays. From the AI Health Index, drawn from each vendor's own published materials and the regulatory record, verified September 28, 2026. No vendor pays for placement.
How much do Isomorphic Labs and Schrödinger leave to the clinician?
In Isomorphic Labs' case, a design agent then works autonomously for two to four days, generating molecules in batches and scoring them against that specification, after which the team selects several diverse compounds to synthesize and test in the lab. Partners run their own preclinical testing on the programs they take forward.
For Schrödinger, the decision to make a molecule stays with the customer's scientists. From the AI Health Index, drawn from each vendor's own published materials and the regulatory record, verified September 28, 2026. No vendor pays for placement.
Related comparisons
Other published head to head assessments involving these vendors or their closest peers. The full set for this category is on the Drug Discovery AI page.
Both records were reviewed on this site in September 2026. Isomorphic's benchmark figures are the company's own, and without the method or weights they cannot be checked from outside.
Ask both what you keep when the engagement ends: the models, the predictions, or only the molecules.